Toujeo (insulin glargine 300 U/mL) begins lowering blood sugar within about six hours of injection, but it does not reach its full, consistent effect until you have been injecting it daily for roughly three to five days. That gap between the first dose and true steady state is one of the most important things to understand about this insulin, because it shapes everything from dose adjustments to how quickly you and your doctor can judge whether a particular dose is working. The reason for this slow build involves how Toujeo forms a dense deposit under the skin, and the practical consequences ripple into dosing, hypoglycemia risk, and day-to-day blood sugar patterns.
What Happens After You Inject
Every time you inject Toujeo into the subcutaneous fat layer, the concentrated insulin solution forms a compact deposit, or depot, under the skin. Because Toujeo packs three times as much insulin into each milliliter compared to standard insulin glargine (the formulation found in Lantus), the depot it creates is physically smaller and has less surface area exposed to surrounding tissue. That smaller surface area is what slows everything down: insulin molecules dissolve off the edge of the deposit gradually rather than flooding into the bloodstream all at once.
Modeling studies confirm that the more compact Toujeo depot and its reduced surface area produce a more gradual and prolonged release of insulin compared to standard-concentration glargine.1PubMed Central. Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL In practical terms, this means there is no sharp spike in blood insulin levels after you inject. Instead, insulin seeps steadily into your bloodstream over the course of the day and beyond. The glucose-lowering activity of Toujeo extends past 24 hours, which is longer than standard glargine and part of why it provides smoother coverage.2PubMed. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
That slow release is what creates the roughly six-hour onset window. You will not see a rapid drop in blood sugar after your first injection the way you might with a rapid-acting mealtime insulin. Toujeo is designed to provide a background hum of insulin activity, not a fast correction.
Reaching Steady State
Onset and steady state are two different things, and mixing them up leads to premature dose changes and frustration. Onset simply means the insulin has started working. Steady state means that the amount of insulin being absorbed from the depot on any given day roughly equals the amount being cleared from your body, so your blood levels of the drug stay consistent from one 24-hour period to the next.
Because Toujeo’s depot releases insulin so slowly and its activity stretches well beyond 24 hours, each new daily injection overlaps with residual activity from the previous days’ injections. It takes about three to five consecutive days of once-daily dosing before these overlapping contributions stack up into a stable, predictable blood insulin level. During those first few days, the full glucose-lowering effect of your dose has not yet been reached. Your fasting blood sugar readings in the first 72 hours do not reflect what the dose will actually do once everything has leveled out.
This is why most prescribing guidance recommends waiting at least three to five days before making upward dose adjustments. If you bump the dose after just one or two days because your fasting glucose still looks high, you risk overshooting once the cumulative effect catches up. Patience during this phase is genuinely important for safety.
How Toujeo Differs from Lantus
Both Toujeo and Lantus contain the same insulin molecule, insulin glargine. The difference is concentration: Toujeo delivers 300 units per milliliter while Lantus delivers 100. That threefold concentration difference changes the physical behavior under the skin in ways that matter clinically.
Compared to Lantus, Toujeo achieves lower and delayed peak concentrations, with insulin exposure distributed more evenly across the 24-hour dosing window.3PubMed. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance In pharmacokinetic and pharmacodynamic studies, Toujeo consistently showed a flatter time-action profile and longer duration of action than the standard-concentration version.4PubMed Central. Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus Think of it this way: Lantus provides a hill-shaped activity curve over the day, with a modest peak somewhere in the middle. Toujeo flattens that hill into something closer to a plateau.
One practical consequence of the flatter profile is that Toujeo’s steady state takes slightly longer to reach than Lantus’s. If you are switching from one to the other, keep in mind that the transition period may involve a few days where your blood sugars behave somewhat unpredictably before the new insulin’s steady-state pattern establishes itself.
Why You May Need More Units
A common surprise when switching to Toujeo is that the dose, measured in units, often needs to go up. A systematic review and meta-analysis comparing the two formulations in both type 1 and type 2 diabetes found that patients on Toujeo required significantly more units of insulin daily than those on Lantus to achieve the same blood sugar control.5PubMed. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis Pediatric data tell a similar story: the total exposure from a unit of Toujeo is roughly 65% of the exposure from the same unit of Lantus, and dose increases of about 10 to 18 percent are typically needed when switching.6PubMed Central. Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
This is not a flaw. It is a direct result of the smaller depot absorbing more slowly. A meaningful fraction of the insulin in that compact deposit gets degraded locally before it ever reaches the bloodstream. The trade-off is the smoother, more extended activity profile. You use more units on paper, but the insulin you do absorb works more evenly. Importantly, Toujeo and Lantus are not interchangeable on a unit-for-unit basis. If you are switching in either direction, your doctor will calculate a conversion rather than simply carrying over the same number.
The Hypoglycemia Advantage
The flatter activity curve has a practical payoff that most people switching to Toujeo care about: fewer lows, especially at night. Because Toujeo does not produce the modest peak in activity that Lantus does, there is less risk of blood sugar dipping too far during the hours when you are asleep and not eating.
Clinical comparisons have found that Toujeo provides similar overall blood sugar control to Lantus but with a lower incidence of hypoglycemia.7Endocrine Practice. Newer Long-Acting Basal Insulin Preparations The reduction in nocturnal hypoglycemia is one of the most consistent findings across trials, and it stems directly from the more even distribution of glucose-lowering activity throughout the dosing interval.3PubMed. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance
This matters during the transition period as well. Even while your body is still building toward steady state with a new Toujeo dose, the risk of a sudden dangerous low is generally lower than it would be with a faster-acting basal insulin. That said, “lower risk” does not mean “no risk.” Monitoring your blood sugar more frequently during the first week of a new dose or a switch remains a sensible precaution.
Real-World Timelines for Blood Sugar Improvement
Understanding onset and steady state is about the drug’s behavior in your body from day to day. But the broader question most people have is how long it takes to actually see their overall blood sugar control improve. The answer is measured in weeks and months, not days.
A large real-world study of people with type 2 diabetes who were starting Toujeo for the first time tracked their progress over a full year. By six months, about a quarter of participants had reached their individual blood sugar target. By twelve months, that figure had roughly doubled to about 45 percent. Average A1C dropped by about 1.5 percentage points at six months and nearly 1.9 points at twelve months, with corresponding improvements in fasting blood sugar.8SpringerLink (Diabetes Therapy). Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
Those numbers reflect the reality that getting to your target A1C with any basal insulin involves gradual titration: small dose increases every few days, guided by fasting blood sugar readings, until you land on the right dose for your body. The three-to-five-day steady-state window is the minimum spacing for each dose adjustment. Stack several adjustments together, and you can see why it takes a few months to dial things in. This is normal and expected. An A1C test taken four weeks into Toujeo therapy is not going to show the full picture.
Factors That Can Change How Toujeo Absorbs
Steady state assumes consistent absorption from day to day. In reality, a number of variables can introduce variability into how quickly and completely the insulin gets from the depot into your bloodstream. These factors affect all subcutaneously injected insulins, but they are worth knowing about because they can explain unexpected blood sugar swings even after steady state should have been reached.9PubMed Central. Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability
- Injection site: The abdomen, thigh, and upper arm absorb insulin at different rates. The abdomen tends to absorb fastest, while the thigh is slower. Rotating within the same general region (for example, different spots on the abdomen) helps keep things consistent. Rotating between regions, say the abdomen one day and the thigh the next, can introduce day-to-day variability in your blood sugar.
- Depth and technique: Injecting too deeply into muscle rather than subcutaneous fat speeds absorption and can cause unexpected lows. Injecting too shallowly can slow it. Using the right needle length for your body composition and pinching a fold of skin when needed helps keep the depth consistent.
- Temperature and exercise: Warm skin increases blood flow and speeds absorption. A hot bath after injecting, vigorous exercise near the injection site, or even a heating pad can pull insulin out of the depot faster than expected. Cold temperatures slow it down.
- Lipodystrophy: Repeatedly injecting into the exact same spot can cause lumps of fatty or scar tissue to form under the skin. These lumps absorb insulin erratically. Rotating injection spots within a region is the main preventive measure.
Toujeo’s compact depot actually offers a modest advantage here. Because the depot is smaller and dissolves more slowly, it is somewhat less sensitive to the blood-flow fluctuations that cause rapid absorption swings with faster-acting insulins. That contributes to the lower day-to-day variability seen in clinical studies. Still, good injection technique and consistent site selection remain important for getting the most predictable results.
Toujeo in Children and Adolescents
Toujeo was originally studied and approved for adults, but it has increasingly been used in younger patients with type 1 diabetes. Pharmacokinetic data from pediatric patients show the same general pattern seen in adults: lower peak concentrations and more gradual release compared to standard glargine.6PubMed Central. Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes The core behavior of the drug, including the days-long march to steady state, is consistent across age groups.
One point that is especially relevant for families: the dose adjustment when switching a child from Lantus to Toujeo follows the same pattern as in adults, typically requiring a 10 to 18 percent increase in units. Because children’s insulin needs can change rapidly with growth, puberty, and activity levels, the titration phase after switching may need closer monitoring than it would for an adult whose daily routine and body composition are more stable.
Timing Your Daily Injection
Because Toujeo’s activity extends well past 24 hours, there is some built-in flexibility in injection timing. If you are an hour or two late one day, the tail end of yesterday’s dose overlaps enough that you are unlikely to see a significant gap in coverage. This is a real practical advantage over shorter-acting basal insulins, where a delayed injection can leave a noticeable window of rising blood sugar.
That said, consistency still matters for the smoothest results. Injecting at roughly the same time each day keeps the overlapping depot contributions as even as possible and makes your fasting blood sugar readings more interpretable for dose titration. Most people pick a time that fits their schedule, whether morning or bedtime, and stick with it. There is no strong pharmacological reason to prefer one time of day over another; the flatter profile means Toujeo works about the same regardless of when you inject it.
During the first week on Toujeo or after any dose change, picking a consistent time becomes even more important. You are trying to build up to steady state, and irregular timing during that window makes it harder to tell whether a high fasting reading means the dose is too low or just that the drug has not fully accumulated yet.
What the Transition Period Actually Feels Like
If you are starting Toujeo for the first time or switching from another basal insulin, the first few days can feel underwhelming. Your fasting blood sugars may still be higher than you want, and you might wonder whether the drug is doing anything at all. This is the steady-state lag in action, not a sign that the medication is failing.
During this period, your doctor will likely ask you to check your fasting blood sugar every morning and hold off on dose changes for at least three to five days. Some titration protocols specify adjusting once a week, which builds in extra margin. The goal is to let each dose reach its full steady-state effect before deciding whether it needs to go up.
People switching from Lantus sometimes notice that their blood sugars run a bit higher initially, even at the converted dose. Part of this is the steady-state lag, and part may be that the initial conversion dose turns out to be slightly conservative. It is common to need one or two small upward adjustments over the first couple of weeks. On the flip side, the nighttime lows that prompted the switch often improve quickly, sometimes from the very first night, because the flatter profile eliminates the mid-sleep insulin peak.
The combination of “daytime numbers still high” and “nighttime lows already better” during the first week is actually a good sign. It means the drug is behaving as expected and that the dose just needs to catch up. Keeping a log of both fasting and overnight readings during this period gives you and your doctor the clearest picture of how the titration is progressing.